NTBL Notable Labs Ltd: Forward Price-to-Revenue Multiple
High barriers to entry for Notable Labs, Ltd. (NTBL) are driven by R&D costs and stringent FDA oversight. The forward P/S multiple helps assess market expectations, where 7.70 reflects the most recent value of the metric. Business efficiency relies on the express delivery of biosamples, while growth potential is based on increasing clinic demand for predictive diagnostics in oncology.
Notable Labs Corp (NTBL) - metric breakdowns and financial figures
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
- financial results and valuation multiples details:
NTBL - Net Profit|Projected Future Earnings Notable Labs, Ltd.|NTBL - Price to Earnings Ratio|Future Price to Earnings Notable Labs Inc.|NTBL - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio Notable Labs Corp|NTBL - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Notable Labs|NTBL - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months notablelabs.com|NTBL - Net earnings per one share growth for the current year|Earnings growth forecast for next year Notable Labs, Ltd.
- total revenue and sales volume data:
Initial company analysis:Notable Labs (NTBL)
AI-driven screening of live cells for oncology therapy selection by Notable Labs, Ltd. (NTBL) creates significant value, which is reflected in the expected price-to-sales ratio. This indicator compares current market capitalization with projected sales volume, allowing investors to instantly determine the extent of the business's market discount or premium relative to competitors while assessing the stability of the cost of capital over time.
Key competitors
Price-to-Projected Revenue Ratio BeiGene ONC|Halozyme Therapeutics, Inc. (HALO) - Market Cap to Future Revenue Ratio|RVMD: Forward Price-to-Revenue Multiple|Ascentage Pharma Corp - Price to Expected Revenue Ratio|CGON: Forward P/S Multiple|urogen.com (URGN) - Forward P/S Multiple|BCAX (Bicara Therapeutics) - Forward P/S Multiple|Price-to-Projected Revenue Ratio PSNL|Price-to-Projected Revenue Ratio Erasca Corp (ERAS)|Price-to-Projected Revenue Ratio DCTH (Delcath Corp)|Forward P/S Multiple YMAB (Y-mAbs Therapeutics)|aurabiosciences.com (AURA) - Market Cap to Future Revenue Ratio|CADL: Forward Price-to-Revenue Multiple|Forward Price to Sales ARAY (Accuray Inc)|sellaslifesciences.com (SLS) - Price-to-Projected Revenue Ratio|ACTU (Actuate Therapeutics Inc) - Price-to-Projected Revenue Ratio|CTOR (Citius Oncology, Inc.) - Forward P/S Multiple|Forward P/S Multiple TuHURA|Forward P/S Multiple TARA|Price-to-Projected Revenue Ratio FATE (Fate Therapeutics Inc)|Price-to-Projected Revenue Ratio Aadi Bioscience WHWK|Market Cap to Expected Sales Ratio TScan Therapeutics Inc (TCRX)|CSBR: Forward Price-to-Revenue Multiple|Forward Price to Sales XBIT (XBiotech Inc.)|cel-sci.com (CVM) - Price-to-Projected Revenue Ratio|OSTX (OS Therapies Inc.) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple RADX|ARTV (Artiva) - Price to Expected Revenue Ratio|Forward P/S Multiple ANL|verupharma.com - Market Cap to Projected Revenue|Tempest Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Xilio Therapeutics Inc (XLO)|RENB - Price-to-Projected Revenue Ratio|MURA (Mural Oncology plc) - Market Cap to Projected Revenue|KAPA (kairospharma.com) - Forward Price-to-Revenue Multiple|OKUR: Price to Expected Revenue Ratio|GDTC (CytoMed Therapeutics Ltd) - Forward P/S Multiple|Price-to-Projected Revenue Ratio CRIS|Price-to-Projected Revenue Ratio Apollomics, Inc. (APLM)|Price-to-Projected Revenue Ratio THAR (Tharimmune Corporation)|Forward P/S Multiple ADVB (Advanced Biomed)|GNPX - Forward Price-to-Revenue Multiple|Calidi Bio - Forward P/S Multiple|SBFM - Forward P/S Multiple|xeneticbio.com (XBIO) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue SLRX|PPBT (Purple Biotech) - Forward P/S Multiple|Forward Price-to-Revenue Multiple AON (AONC)|Forward P/S Multiple BGNE|CKPT - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Elevation Oncology, Inc. ELEV|Forward Price to Sales ICAD|IKNA: Forward Price-to-Revenue Multiple|Forward Price to Sales VIRX (Viracta Therapeutics)|MOR: Forward P/S Multiple|Forward Price-to-Revenue Multiple NAYA Biosciences Inc|Forward Price-to-Revenue Multiple AAPGV
